Bristol-Myers Squibb (BMY) Breaks Through Resistance at $31.30 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. By Adrienne Chilton. |
